Page last updated: 2024-08-05 15:34:14
HIV-1 integrase inhibitor
An inhibitor of HIV-1 integrase, an enzyme required for the integration of the genetic material of the retrovirus into the DNA of the infected cells.
ChEBI ID: 67268
Members (12)
| Member | Definition | Class |
|---|---|---|
| australifungin | A carbobicyclic compound that is 4a,5,6,7,8,8a-hexahydronaphthalen-1(4H)-one substituted by hydroxy groups at positions 2, 5 and 8, a (2Z)-3-hydroxyprop-2-enoyl group at position 4, methyl groups at positions 4 and 7 and a 2R-octan-2-yl group at position 3 (the 4S,4aR,5S,7R,8R,8aS stereoisomer). It is isolated from the fermentation extracts of Sporormiella australis and exhibits antifungal activity by interfering with the fungal lipid metabolism. | australifungin |
| bictegravir | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1. | bictegravir |
| chicoric acid | chicoric acid | |
| complestatin | A heterodetic cyclic peptide which is a atropisomer of complestatin. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity. | chloropeptin II; isocomplestatin |
| dolutegravir | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. | dolutegravir |
| equisetin | A member of the class of tetramic acids that is trichosetin in which the hydrogen attached to the lactam nitrogen has been replaced by a methyl group. It is produced by the filamentous fungus Fusarium heterosporum. | equisetin |
| gsk1265744 | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. | cabotegravir |
| integric acid | An eremophilane sesquiterpenoid with anti-HIV-1 activity. It is isolated from Xylaria sp. MF6254. | integric acid |
| jtk-303 | A quinolinemonocarboxylic acid that is 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid substited at position 1 by a 1-hydroxy-3-methylbutan-2-yl group and at position 6 by a 3-chloro-2-fluorobenzyl group (the S-enantiomer). It is used in combination therapy for the treatment of HIV-1 infection. | elvitegravir |
| laurolitsine | An aporphine alkaloid that is noraporphine substituted by hydroxy groups at positions 2 and 9 and methoxy groups at positions 1 and 10. Isolated from Litsea glutinosa and Lindera chunii, exhibits inhibitory activity against HIV-1 integrase. | laurolistine |
| neuroprotectin a | A heterodetic cyclic peptide that is chloropeptin II in which the indole moiety is oxidised to the corresponding 2-oxindole. It is a HIV-1 integrase inhibitor isolated from Streptomyces. | complestatin A |
| raltegravir | A pyrimidone that is pyrimidin-4(3H)-one in which the hydrogens at positions 2, 3, 5 and 6 are replaced by 2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl, methyl, hydroxy, and N-[(4-fluorophenyl)methyl]aminoacyl groups, respectively. It is an antiretroviral drug used for treatment of HIV infection. | raltegravir |
Research
Studies (1,992)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (0.20) | 18.7374 |
| 1990's | 26 (1.31) | 18.2507 |
| 2000's | 127 (6.38) | 29.6817 |
| 2010's | 1,021 (51.26) | 24.3611 |
| 2020's | 814 (40.86) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 319 (14.21%) | 5.53% |
| Reviews | 239 (10.65%) | 6.00% |
| Case Studies | 133 (5.92%) | 4.05% |
| Observational | 83 (3.70%) | 0.25% |
| Other | 1,471 (65.52%) | 84.16% |
Protein Targets (71)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 0.0063 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 16.0620 | 2 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 3.9811 | 1 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.7943 | 1 | 1 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 16.0620 | 2 | 2 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 0.0617 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.5845 | 1 | 1 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 22.5272 | 4 | 8 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 37.2212 | 1 | 2 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 22.9664 | 2 | 2 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 40.0466 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 0.0063 | 1 | 1 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 0.0063 | 1 | 1 |
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 1 | 1 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 15.8489 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 70.9220 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 0.0273 | 1 | 1 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 3.3491 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 29.8470 | 1 | 1 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 23.7083 | 1 | 1 |
| polyprotein | Zika virus | Potency | 37.2212 | 1 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 19.9826 | 2 | 2 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 32.2774 | 3 | 3 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 10.6822 | 1 | 1 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 10.6822 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 0.0352 | 1 | 2 |
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 95.0000 | 2 | 2 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 48.5000 | 2 | 2 |
| C-C chemokine receptor type 1 | Homo sapiens (human) | Ki | 0.0050 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 95.0000 | 2 | 2 |
| Chain A, PFV integrase | Human spumaretrovirus | IC50 | 0.0517 | 1 | 9 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 70.0000 | 2 | 2 |
| Cytochrome P450 2A6 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 67.0000 | 1 | 2 |
| Cytochrome P450 2C8 | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 70.0000 | 2 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 80.0000 | 3 | 4 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 58.5000 | 2 | 2 |
| D | Rattus norvegicus (Norway rat) | IC50 | 2.5000 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 6.8000 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | IC50 | 0.0150 | 1 | 1 |
| Integrase | Human immunodeficiency virus 1 | IC50 | 2.4322 | 78 | 103 |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | IC50 | 5,011.8700 | 1 | 1 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 25.1189 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 1,278.3495 | 4 | 4 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 25.1189 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 302.0000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 302.0000 | 1 | 1 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 | 41.0909 | 6 | 11 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.0180 | 1 | 1 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | Ki | 0.0238 | 2 | 2 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 0.0975 | 2 | 2 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 950.5590 | 2 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 16.5000 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| T-cell surface glycoprotein CD4 | Homo sapiens (human) | IC50 | 0.1300 | 1 | 1 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | Ki | 1,400.0000 | 1 | 1 |
| Tyrosine-protein phosphatase YopH | Yersinia enterocolitica | IC50 | 379.0000 | 1 | 1 |
| Tyrosine-protein phosphatase YopH | Yersinia enterocolitica | Ki | 40.4000 | 2 | 2 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 153.3333 | 3 | 3 |
| Vesicular acetylcholine transporter | Rattus norvegicus (Norway rat) | Ki | 4.5230 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 246.7000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 246.7000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 246.7000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 246.7000 | 1 | 1 |
Activation Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Integrase | Human immunodeficiency virus 1 | EC50 | 0.0024 | 6 | 6 |
| Integrase | Human immunodeficiency virus 2 | EC50 | 0.0023 | 1 | 1 |
| Integrase | Human immunodeficiency virus 1 | Kd | 3.0000 | 1 | 1 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | Kd | 1,600.0000 | 1 | 1 |
Other Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Integrase | Human immunodeficiency virus 1 | C50 | 0.0110 | 1 | 2 |
| Integrase | Human immunodeficiency virus 1 | MI50 | 100.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Km | 21.0000 | 1 | 1 |